Geriatric chronic kidney disease patients benefit from SGLT2 inhibition

New research uncovers the potential benefits and risks of sodium-glucose cotransporter 2 (SGLT2) inhibitors for adults aged 80 years or older with chronic kidney disease (CKD). The findings will be presented at ASN Kidney Week 2026 October 22–25.

Read Original Copy